Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.53 |
| ▸ | CCR1 | P32246 | 7/20 | 0.46 |
| ▸ | CYP51A1 | Q16850 | 5/20 | 0.45 |
| ▸ | MC4R | P32245 | 5/20 | 0.45 |
| ▸ | PYGL | P06737 | 1/20 | 0.44 |
| ▸ | CALCA | P06881 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4700104 | 0.88 | TACR1 (0.51) | TACR1CCR1CYP51A1MC4RPYGL | |
| SCHEMBL4700113 | 0.86 | TACR1 (0.51) | TACR1CCR1CYP51A1MC4RPYGL | |
| SCHEMBL4697689 | 0.86 | TACR1 (0.49) | TACR1CCR1CYP51A1MC4RPYGL | |
| SCHEMBL4697659 | 0.85 | TACR1 (0.51) | TACR1CCR1CYP51A1MC4RPYGL | |
| SCHEMBL4698174 | 0.85 | TACR1 (0.53) | TACR1CCR1MC4R | |
| SCHEMBL4680475 | 0.85 | TACR1 (0.52) | TACR1CCR1CYP51A1MC4RPYGL | |
| SCHEMBL4676043 | 0.84 | TACR1 (0.55) | TACR1CCR1MC4R | |
| SCHEMBL6254758 | 0.84 | TACR1 (0.55) | TACR1CCR1MC4R | |
| SCHEMBL4697553 | 0.84 | TACR1 (0.54) | TACR1CCR1CYP51A1MC4RPYGL | |
| SCHEMBL4697653 | 0.84 | TACR1 (0.50) | TACR1CCR1CYP51A1MC4RPYGL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1416933-B1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEM INC (US) | 2008-01-02 | — | — | EP | claimed |
| US-6977264-B2 | Substituted piperidines and methods of use | AMGEN INC. (US) | 2005-12-20 | — | — | US | claimed |
| US-20040006067-A1 | Substituted piperidines and methods of use | AMGEN INC. | 2004-01-08 | — | — | US | claimed |
| EP-1416933-B1 | SUBSTITUTED PIPERIDINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR | AMGEM INC (US) | 2008-01-02 | — | — | EP | disclosed |
| US-6977264-B2 | Substituted piperidines and methods of use | AMGEN INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20040006067-A1 | Substituted piperidines and methods of use | AMGEN INC. | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006067-A1 | Substituted piperidines and methods of use | MC4R, MC5R, MC1R | TACR1 48/4885CCR1 581/4885CYP51A1 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.